NASDAQ:XENEXenon Pharmaceuticals Stock Price, Forecast & News

Xenon Pharmaceuticals' stock was trading at $12.71 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, XENE shares have increased by 17.2% and is now trading at $14.90. View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xenon Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Xenon Pharmaceuticals.

Xenon Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Xenon Pharmaceuticals.

Xenon Pharmaceuticals Inc (NASDAQ:XENE) issued its earnings results on Thursday, May, 21st. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.32) by $0.10. The biopharmaceutical company earned $7.08 million during the quarter, compared to analysts' expectations of $7.50 million. View Xenon Pharmaceuticals' earnings history.

3 brokers have issued 12-month price targets for Xenon Pharmaceuticals' shares. Their forecasts range from $23.00 to $25.00. On average, they expect Xenon Pharmaceuticals' stock price to reach $24.00 in the next twelve months. This suggests a possible upside of 61.1% from the stock's current price. View analysts' price targets for Xenon Pharmaceuticals.

Media coverage about XENE stock has trended somewhat positive on Monday, according to InfoTrie Sentiment. The research group ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Xenon Pharmaceuticals earned a news impact score of 1.4 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 3.0 out of 10, meaning that recent media coverage is unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutXenon Pharmaceuticals.

Some companies that are related to Xenon Pharmaceuticals include SAGE Therapeutics (SAGE), Madrigal Pharmaceuticals (MDGL), Ironwood Pharmaceuticals (IRWD), Pacira Biosciences (PCRX), Epizyme (EPZM), Aurinia Pharmaceuticals (AUPH), Corcept Therapeutics (CORT), Xencor (XNCR), IGM Biosciences (IGMS), Ligand Pharmaceuticals (LGND), Eidos Therapeutics (EIDX), Theravance Biopharma (TBPH), Arvinas (ARVN), Opko Health (OPK) and Dicerna Pharmaceuticals (DRNA). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Xenon Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Novavax (NVAX), Viking Therapeutics (VKTX), Nektar Therapeutics (NKTR), Progenics Pharmaceuticals (PGNX), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Arbutus Biopharma (ABUS), Crispr Therapeutics (CRSP) and Dynavax Technologies (DVAX).

Xenon Pharmaceuticals trades on the NASDAQ under the ticker symbol "XENE."

Xenon Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Orbimed Advisors LLC (4.76%), Bank of New York Mellon Corp (1.93%), Rock Springs Capital Management LP (1.43%), Driehaus Capital Management LLC (1.32%), Ikarian Capital LLC (1.27%) and Vivo Capital LLC (1.13%). Company insiders that own Xenon Pharmaceuticals stock include Frank A Holler, Mohammad Azab and Simon N Pimstone. View institutional ownership trends for Xenon Pharmaceuticals.

XENE stock was sold by a variety of institutional investors in the last quarter, including Soleus Capital Management L.P., Squarepoint Ops LLC, JPMorgan Chase & Co., Falcon Point Capital LLC, and State Street Corp. Company insiders that have sold Xenon Pharmaceuticals company stock in the last year include Frank A Holler, Mohammad Azab, and Simon N Pimstone. View insider buying and selling activity for Xenon Pharmaceuticals.

XENE stock was acquired by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Rock Springs Capital Management LP, Driehaus Capital Management LLC, Bank of New York Mellon Corp, Vivo Capital LLC, Ghost Tree Capital LLC, Ikarian Capital LLC, and Burrage Capital Management LLC. View insider buying and selling activity for Xenon Pharmaceuticals.

Shares of XENE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of XENE stock can currently be purchased for approximately $14.90.

Xenon Pharmaceuticals has a market capitalization of $520.84 million and generates $6.83 million in revenue each year. The biopharmaceutical company earns $-41,600,000.00 in net income (profit) each year or ($1.54) on an earnings per share basis. Xenon Pharmaceuticals employs 89 workers across the globe.

The official website for Xenon Pharmaceuticals is www.xenon-pharma.com.

Xenon Pharmaceuticals' mailing address is 200 - 3650 GILMORE WAY, BURNABY A1, V5G 48W. The biopharmaceutical company can be reached via phone at 604-484-3300 or via email at [email protected]